Novartis AG - ADR


Market Cap$232.18B

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Novartis AG - ADRNovartis AG - ADR15.23.53%38%5.30.7

Earnings Call Q4 2023

January 31, 2024 - AI Summary

Novartis reported strong full-year results for 2023, with sales up 10% and core operating income up 18% in constant currencies.
The company provided updated guidance for 2024, expecting mid-single digit sales growth and high single-digit core operating income growth. This guidance is considered prudent due to the potential impact of generics and assumes no US generic entry for Entresto in 2024.
Novartis extended its midterm guidance, projecting a 5% constant currency sales growth from 2023 to 2028 and aiming for a core operating income margin of 40% or higher by 2027.

Exclusive for Stockcircle Pro members

Sign upSign Up

Target Price by Analysts

2.1% upsideNovartis AG Target Price DetailsTarget Price

Current Fair Value

3.1% downside

Overvalued by 3.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$232.18 Billion
Enterprise Value$249.77 Billion
Dividend Yield$3.7395 (3.53%)
Earnings per Share$7.34
Outstanding Shares2,189,930,497
Avg 30 Day Volume1,203,484


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio15.23
Price to Sales5.29
Price to Book Ratio5.87
Enterprise Value to Revenue5.48
Enterprise Value to EBIT23.58
Enterprise Value to Net Income16
Total Debt to Enterprise0.11
Debt to Equity0.69

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Novartis AG

CEO: Vasant Narasimhan

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segm...